Erythromycin Estolate Analysis Service

Erythromycin Estolate Analysis Service

Erythromycin Estolate (Ery-Est) Analysis for Pharmaceutical Quality Control

CD BioGlyco provides comprehensive and precise analysis services for Ery-Est within the pharmaceutical field. Our focus encompasses qualitative and quantitative detection of this compound across diverse pharmaceutical formulations, along with thorough assessments of its physicochemical properties. Leveraging our expertise, we ensure accurate identification and characterization of Ery-Est, supporting extensive research applications ranging from pharmaceutical development to biomarker studies.

Ery-Est, the lauryl sulfate ester of propionyl erythromycin, is a topical macrolide antibiotic with broad-spectrum antibacterial activity. It enters the bacterial cell membrane and precisely binds to the 50S subunit of the bacterial ribosome, disrupting the synthesis of bacterial proteins. The bacteriostatic or bactericidal effect of Ery-Est is determined by the drug concentration at the infection site and the susceptibility of the specific organism.

Fig.1 The structure of Ery-Est. (CD BioGlyco)Fig.1 The structure of Ery-Est. (CD BioGlyco)

CD BioGlyco's Ery-Est analysis service primarily focuses on qualitative and quantitative analysis. Our method guarantees a meticulous assessment of Ery-Est, encompassing considerations related to its identity and concentration. The service encompasses precise analytical methods that contribute to the accurate characterization of this macrolide antibiotic, providing valuable insights for pharmaceutical development and quality assurance.

For the analysis of Ery-Est, our methods are available for several preparations.

  • Ery-Est tablets
  • Ery-Est capsules
  • Ery-Est oral suspension
  • Ery-Est for oral suspension
  • Ery-Est and sulfisoxazole acetyl oral suspension
  • Erythromycin ethylsuccinate
  • Erythromycin ethylsuccinate injection

Our analysis service includes but is not limited

Fig.2 The standard content of Ery-Est analysis. (CD BioGlyco)Fig.2 The standard content of Ery-Est analysis. (CD BioGlyco)

Publication Data

Technology: Plaque assay, Drug cytotoxicity assay, Immunofluorescence staining assay, RNase digestion assay and RT-qPCR

Journal: Frontiers in Cellular and Infection Microbiology

IF: 5.7

Published: 2022

Results: In this study, it was found that Ery-Est, a lauryl sulfate ester of propionyl erythromycin (Ery), effectively inhibited HCoV-OC43 infection in various host cells. Ery and Ery-Est are macrolide antibiotics used for bacterial infections, and Ery-Est showed significant antiviral activity against HCoV-OC43. Plaque reduction and immunofluorescence assays demonstrated dose-dependent inhibition, with Ery-Est exhibiting robust suppression of HCoV-OC43 infection in different host cells without apparent toxicity. This suggests its potential as an antiviral agent.

Fig.3 The anti-HCoV-OC43 activity of Ery-Est. (Wang, et al., 2022)Fig.3 The anti-HCoV-OC43 activity of Ery-Est. (Wang, et al., 2022)


  • Our service can be used in guaranteeing the quality and compliance of pharmaceutical formulations that incorporate Ery-Est.
  • By offering qualitative and quantitative analysis, CD BioGlyco contributes to formulation optimization, potency determination, and quality control processes.
  • This aids pharmaceutical researchers and developers in refining drug formulations, assessing their efficacy, and maintaining adherence to regulatory standards throughout the development lifecycle.


  • Our service focuses on both qualitative and quantitative detection of Ery-Est in different pharmaceutical formulations, ensuring precision in results.
  • We cover a wide range of testing parameters, including characterization, physical properties, infrared absorption spectra identification, and more.
  • We provide tailored solutions to meet specific requirements, allowing clients to choose the scope and depth of the analysis based on their needs.

CD BioGlyco offers a comprehensive Ery-Est analysis service, moreover, we also offer a suite of Pharmaceutical and Biological Analyses. Tailored to address the varied requirements of Pharmaceutical Research, our services guarantee precise and dependable outcomes across a range of applications. From qualitative and quantitative analysis of Ery-Est to broader pharmaceutical analysis, our research team and advanced analytical methods contribute to the success of drug development and quality control processes. Trust CD BioGlyco for precise and tailored service in the field of pharmaceutical analysis and please feel free to contact us!


  1. Wang, X.; et al. Erythromycin estolate is a potent inhibitor against HCoV-OC43 by directly inactivating the virus particle. Frontiers in Cellular and Infection Microbiology. 2022, 12: 905248.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.